Source: Eur Respir J, 55 (6) 1901105; 10.1183/13993003.01105-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Philipp Kolb, Chandak Upagupta, Megan Vierhout, Ehab Ayaub, Pierre Simon Bellaye, Jack Gauldie, Chiko Shimbori, Mark Inman, Kjetil Ask, Martin R.J. Kolb. The importance of interventional timing in the bleomycin model of pulmonary fibrosis. Eur Respir J, 55 (6) 1901105; 10.1183/13993003.01105-2019

Member's Comments

No comment yet.

Related content which might interest you: The histopathalogical evaluation of administration route of bleomycin in pulmonary fibrosis model and contribution of smoking to development of fibrosis Source: Annual Congress 2007 - Pathogenesis of idiopathic interstitial pneumonia including idiopathic pulmonary fibrosis Year: 2007 The role of pulmonary structural cells in pulmonary fibrosis in a model of hypersensitivity pneumonitis Source: Annual Congress 2010 - Immune modulation of airways diseases Year: 2010 Estimation of antibiotic effect on the development of bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Clinical features of combined pulmonary fibrosis and emphysema Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 The effectiveness of pulmonary rehabilitation including occupational therapy in patients with chronic pulmonary emphysema Source: Eur Respir J 2002; 20: Suppl. 38, 376s Year: 2002 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 The effectiveness of pulmonary rehabilitation in patients diagnosed with interstitial pulmonary fibrosis Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020 Clinical significance of combined pulmonary fibrosis and emphysema Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Combined pulmonary fibrosis and emphysema: a high-pressure situation Source: Eur Respir J 2010; 35: 9-11 Year: 2010 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008